KUALA LUMPUR (August 2026) — Qinhuangdao Taizhi Medical Technology Co., Ltd. (Taizhi Medical), a global compliance-driven manufacturer operating at massive capacity for medical devices and personal protective equipment (PPE), officially announced today the launch of its accelerated medical product registration and listing regulatory approvals under the Medical Device Authority (MDA) of the Ministry of Health Malaysia.

This strategic milestone indicates that Taizhi Medical, following its rigorous compliance audits under European CE MDR and US FDA systems, is aggressively deploying its manufacturing credentials into the core of Southeast Asia's public tenders and premium private clinical ecosystems.

According to the official MDA technical evaluation criteria, Taizhi Medical's regulatory compliance division is ready to submit its comprehensive ISO 13485 Quality Management technical dossiers. To address the high-frequency procurement bottlenecks within the regional market, the initial product portfolios fast-tracked into the compliance evaluation window cover Taizhi's premier clinical lines: including European Type IIR / US Level 3 High-Fluid-Barrier Surgical Masks, Medical Protective Masks.

Operating 36 fully automated production lines with a massive daily capacity of 2,000,000 pieces, Taizhi Medical's source-factory scale has already triggered a strong siphon effect across the Asia-Pacific institutional medical procurement network. 

Following its successful showcase at the Association of Private Hospitals of Malaysia (APHM) International Healthcare Conference & Exhibition in Kuala Lumpur last month, Taizhi Medical has leveraged its machine-automated product lines guarantees to successfully secure extensive procurement intention frameworks with dozens of premier international private hospital networks across Malaysia and the broader ASEAN region.

 "Hospital terminals represent the most complex yet consistently stable tier in global healthcare sourcing," stated Lily, Business Development Manager of Taizhi Medical. "Private medical centers in Malaysia maintain strict standards matching European and American clinical metrics for fluid barrier protection and logistics continuity. During this 30-day MDA registration window, Taizhi is deploying a customized VIP Protocol covering complimentary sample audits and strategic price-comparison models for our partnered institutions. Our target is clear: on Day One of the official MDA license release, our direct-factory, cost-optimized sterile and non-sterile portfolios will move into instant mass production and rapid dispatch to build a highly cost-efficient shield for frontline healthcare workers."

 Industry analysts point out that Taizhi Medical's latest entry into the Malaysia MDA registry not only allows it to eliminate third-party trading markups through sharp tiered factory-direct pricing, but also perfectly positions the company to lock down major 2026/2027 national medical stockpile allocations. Taizhi Medical's regular-army globalized expansion is hitting a powerful growth surge.